Cancer Incidence and Mortality After Treatment with Folic Acid and Vitamin B12
Overview
Authors
Affiliations
Context: Recently, concern has been raised about the safety of folic acid, particularly in relation to cancer risk.
Objective: To evaluate effects of treatment with B vitamins on cancer outcomes and all-cause mortality in 2 randomized controlled trials.
Design, Setting, And Participants: Combined analysis and extended follow-up of participants from 2 randomized, double-blind, placebo-controlled clinical trials (Norwegian Vitamin Trial and Western Norway B Vitamin Intervention Trial). A total of 6837 patients with ischemic heart disease were treated with B vitamins or placebo between 1998 and 2005, and were followed up through December 31, 2007.
Interventions: Oral treatment with folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d) and vitamin B(6) (40 mg/d) (n = 1708); folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d) (n = 1703); vitamin B(6) alone (40 mg/d) (n = 1705); or placebo (n = 1721).
Main Outcome Measures: Cancer incidence, cancer mortality, and all-cause mortality.
Results: During study treatment, median serum folate concentration increased more than 6-fold among participants given folic acid. After a median 39 months of treatment and an additional 38 months of posttrial observational follow-up, 341 participants (10.0%) who received folic acid plus vitamin B(12) vs 288 participants (8.4%) who did not receive such treatment were diagnosed with cancer (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.03-1.41; P = .02). A total of 136 (4.0%) who received folic acid plus vitamin B(12) vs 100 (2.9%) who did not receive such treatment died from cancer (HR, 1.38; 95% CI, 1.07-1.79; P = .01). A total of 548 patients (16.1%) who received folic acid plus vitamin B(12) vs 473 (13.8%) who did not receive such treatment died from any cause (HR, 1.18; 95% CI, 1.04-1.33; P = .01). Results were mainly driven by increased lung cancer incidence in participants who received folic acid plus vitamin B(12). Vitamin B(6) treatment was not associated with any significant effects.
Conclusion: Treatment with folic acid plus vitamin B(12) was associated with increased cancer outcomes and all-cause mortality in patients with ischemic heart disease in Norway, where there is no folic acid fortification of foods.
Trial Registration: clinicaltrials.gov Identifier: NCT00671346.
Recent Advances on the Role of B Vitamins in Cancer Prevention and Progression.
Frost Z, Bakhit S, Amaefuna C, Powers R, Ramana K Int J Mol Sci. 2025; 26(5).
PMID: 40076592 PMC: 11900642. DOI: 10.3390/ijms26051967.
Biological, dietetic and pharmacological properties of vitamin B.
Siatka T, Matus M, Moravcova M, Harcarova P, Lomozova Z, Matousova K NPJ Sci Food. 2025; 9(1):30.
PMID: 40075081 PMC: 11904035. DOI: 10.1038/s41538-025-00396-w.
Qi P, Chen L, Ma A, Zhang Y, Lin H, Shi W Discov Oncol. 2025; 16(1):204.
PMID: 39969704 PMC: 11839550. DOI: 10.1007/s12672-025-01905-9.
Zhang J, Yue D, Zhang H Sci Rep. 2025; 15(1):3327.
PMID: 39865092 PMC: 11770194. DOI: 10.1038/s41598-025-87129-x.
Folate metabolism in myelofibrosis: a missing key?.
Cerreto G, Pozzi G, Cortellazzi S, Pasini L, Di Martino O, Mirandola P Ann Hematol. 2025; 104(1):35-46.
PMID: 39847116 PMC: 11868374. DOI: 10.1007/s00277-024-06176-y.